Amgen and UCB have re-filed for FDA approval of osteoporosis drug romosozumab one year after the agency rejected a submission on safety grounds. The revised filing pools all the phase 3 data in a bid to show the sclerostin-targeting antibody has a positive risk-benefit profile.
Romosozumab looked well set to come to market when it aced its first phase 3 in September 2016. That changed in May 2017 when a second phase 3 detected a new cardiovascular safety signal. Two months later, the FDA rejected a filing for approval of romosozumab in postmenopausal women with osteoporosis.
Now, Amgen and UCB have gone back to the FDA. The new filing features data from the original, 7,180-person person phase 3 trial that formed the backbone of the original submission, plus results from two other studies.
One of the other studies is the second phase 3 of romosozumab in 4,093 postmenopausal women with osteoporosis who experienced a fracture. That clinical trial found romosozumab was better than alendronate at reducing fractures but also uncovered the safety signal. The third set of data included in the filing comes from a 245 person study of the effect of romosozumab in men.
Amgen and UCB are hoping that when the FDA gets to analyze all the safety and efficacy data it will conclude the benefits of romosozumab outweigh the risks. However, there remains a chance the FDA will turn the drug down or impose a restrictive label that limits its commercial prospects.
A restrictive label could see romosozumab struggle to live up to the blockbuster forecasts made by analysts prior to the safety scare. If romosozumab comes to market, it will face competition from Eli Lilly’s Forteo and Radius Health’s Tymlos. Romosozumab has some advantages over the competition, such as monthly dosing, but these could be swept away by cardiovascular safety concerns.
By: Nick Paul Taylor
Source: Fierce Biotech
Novo Nordisk’s fast-growing weight loss med Wegovy just added a new cardiovascular FDA approval to its label, likely enabling the med’s superstar status to reach new levels. The med is now the first weight loss treatment to score an FDA nod to reduce the risk of cardiovascular death, heart attack and stroke in adult patients with cardiovascular disease who have obesity or are overweight.
Galderma has announced a price range of CHF 49 to CHF 53 ($55.8 to $60.3) per share for floatation on the SIX Swiss Exchange. The Swiss skincare company, which revealed its intention to conduct an initial public offering (IPO) earlier in March, will have 40,453,467 new shares available. The offering also consists of 276,909 existing shares.
Taking over as CEO for an aging company in dire financial straits and in need of a slim-down was a challenging assignment for Christophe Bourdon. But under Bourdon’s watch, Leo Pharma is taking steps toward a rebound. Last month, the 115-year-old Danish private company reported that it cut its operating costs by 14% in 2023 while increasing its revenues by 7%.